Alembic Pharma USFDA nod for Bosutinib 400 mg (2026)

What Alembic announced

Alembic Pharmaceuticals Ltd told exchanges on January 12, 2026 that it has received tentative approval from the US Food and Drug Administration (USFDA) for Bosutinib tablets used in certain cancer treatments. The clearance is for a supplemental abbreviated new drug application (sANDA) for the 400 mg strength, as disclosed in a regulatory filing. The development matters because USFDA decisions directly shape an Indian drugmaker’s ability to participate in the US generics market, especially in oncology where volumes and compliance expectations are high. Alembic positioned the update as an incremental step in the molecule’s lifecycle, since it already has approvals in other strengths. The company also clarified that its approved ANDA is therapeutically equivalent to the reference listed drug (RLD). The RLD cited is Bosulif tablets, 400 mg, marketed by PF Prism C.V. The announcement came during market hours, and the stock was marginally lower around the time of the update.

The USFDA decision and filing route

The company said the USFDA has granted tentative approval for its sANDA for Bosutinib tablets, 400 mg. A supplemental ANDA is typically used when a company is seeking an additional strength or another change under an existing ANDA framework. Alembic’s filing references that the product is therapeutically equivalent to Bosulif 400 mg, which is an important classification for substitution in the US market. The regulatory filing did not disclose a launch date, and the approval is described as “tentative” rather than “final.” The company’s update focuses on the specific strength, suggesting it is a targeted expansion rather than a completely new molecule entry. The filing also reiterates the product’s equivalence to the RLD, which is a standard but essential piece of information for US generic approvals. No additional manufacturing or facility details were provided in the disclosure.

What Bosutinib is used for

Alembic said Bosutinib is indicated for adult patients with chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). The company’s filing also notes use cases for newly diagnosed patients, and for those who are resistant or intolerant to prior therapy. In addition, Bosutinib is indicated for adult patients with accelerated or blast phase Ph+ CML who have shown resistance or intolerance to prior therapy. The company also described Bosutinib as a kinase inhibitor in a separate market update. These indications position the product within a specialised oncology segment where prescriber adoption is influenced by clinical protocols and availability. Alembic’s communication was limited to approved indications and did not include any claims on clinical differentiation. It also did not provide pricing or expected market share assumptions.

What “tentative approval” signals

Tentative approval indicates that the USFDA has determined the application meets required standards for quality, safety, and efficacy, but the product cannot yet be marketed in the US due to remaining conditions such as patent or exclusivity constraints. Alembic did not specify the reason the approval is tentative in its filing. The practical implication is that Alembic has cleared a major regulatory checkpoint for the 400 mg strength, while commercial entry will depend on the resolution of outstanding barriers. For investors, this distinction is material because a tentative approval does not automatically translate into immediate revenue. Still, tentative clearances are often tracked as pipeline progress, particularly for companies with active US portfolios. In this case, the update adds one more regulatory milestone tied to an existing molecule where Alembic already has other strengths approved.

How this fits into Alembic’s Bosutinib approvals

Alembic said it had previously received final approval for its ANDA Bosutinib tablets in the 100 mg and 500 mg strengths. The 400 mg strength, now tentatively approved via sANDA, broadens the available dosage portfolio for the molecule. In lifecycle terms, adding a widely used strength can matter because prescription patterns in CML can depend on dosing requirements and patient tolerance. The company’s market note explicitly called the 400 mg dosage “an additional opportunity” in the molecule’s lifecycle. However, Alembic did not quantify what portion of prescriptions are written for the 400 mg strength, nor did it comment on competitive intensity. The update is narrowly focused on regulatory status and product equivalence.

Stock reaction on NSE

Alembic Pharma was trading marginally lower after the announcement. At around 2.34 PM, the stock was quoted at ₹799.30 on the NSE, compared with the previous close of ₹799.95. The counter recorded an intraday high of ₹804.15 and an intraday low of ₹786, as per the market update included in the text. The price action suggests the disclosure was absorbed without a sharp immediate re-rating during that session. The announcement did not include forward guidance or any quantified financial impact, which can limit how much the market reacts on the day. Still, USFDA updates are closely watched for signals on execution in regulated markets.

Market size cited for the 400 mg strength

Alembic disclosed that Bosutinib tablets, 400 mg, had an estimated market size of $151 million in the US for the year ended September 2025. The company did not cite the source in the excerpt provided, but the figure was presented as part of the disclosure. Market size estimates are often used as a directional indicator of addressable opportunity, although actual realised sales depend on launch timing, competitive entry, pricing, and supply reliability. The company did not provide any estimate of its potential share of this market. It also did not indicate whether the opportunity is expected to be immediate following a future final approval or subject to extended timelines. The $151 million figure nevertheless provides context for why the 400 mg strength is meaningful for the molecule’s US commercial profile.

Broader context: Alembic’s US oncology flow

The text also references other USFDA outcomes for Alembic in oncology and related therapies, including approvals for generic Dasatinib tablets across multiple strengths and for Doxorubicin Hydrochloride Liposome injection in specified vial strengths. For Dasatinib tablets, the text cites an estimated market size of USD 1,017 million for the 12 months ended September 2025 (for the listed strengths), and for Doxorubicin Hydrochloride Liposome injection it cites an estimated market size of $19 million for the 12 months ended March 2025 (for the specified vial strengths). These disclosures, while separate from the Bosutinib update, illustrate that Alembic’s US strategy includes a steady cadence of filings and approvals in complex and oncology-linked categories. One separate report in the provided text also notes that Alembic posted a 17% year-on-year increase in revenue to around ₹1,770 crore in the fourth quarter of FY25. The Bosutinib 400 mg tentative approval adds to this broader picture of execution, but the company has not connected this specific approval to any revenue target.

Key facts at a glance

What to watch next

The immediate next milestone is whether Alembic receives final approval that would allow commercial marketing of Bosutinib 400 mg in the US. The company’s disclosure does not state a timeline for that transition, and it does not specify the conditions keeping the approval tentative. Investors will likely track further regulatory updates, including any subsequent final approval notice or launch-related disclosures. In the near term, the update is best read as incremental regulatory progress that expands Alembic’s Bosutinib portfolio beyond the strengths that already have final approval. Any financial impact will depend on the timing and terms of eventual market entry, which were not provided in the filing.